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OBJECTIVE To determine whether current vascular Chlamydia pneumoniae (CPn) infection as diagnosed
by circulating CPn DNA is more common in subjects with coronary artery disease (CAD).
BACKGROUND Serological, pathological and animal studies have associated CPn with CAD and preliminary
trials suggest antibiotics may prevent adverse coronary events. C. pneumoniae is thought to
disseminate systemically within macrophages. We therefore detected CPn DNA in blood to
determine whether its presence was a predictor of CAD.
METHODS One thousand, two hundred and five subjects attending for diagnostic and interventional
coronary arteriography were recruited. The mononuclear cell layer and platelets were
separated from collected blood and the polymerase chain reaction (PCR) was used to detect
CPn DNA.
RESULTS Circulating CPn DNA was found in 8.8% of 669 men with CAD compared with 2.9% of 135
men with normal coronary arteries (odds ratio [OR] 3.2, 95% confidence interval [CI]
1.1–8.9). In men with CAD, those with CPn DNA had higher mean platelet counts than
those without CPn DNA. Monocyte counts and indirect fibrinogen levels were also raised but
not significantly so. By contrast, no association of circulating CPn DNA and CAD was seen
in women.
CONCLUSIONS Circulating CPn DNA is a predictor of CAD in men. Unlike serology, it is a specific indicator
of current infection and is a means of identifying subjects who may potentially benefit from
antichlamydial therapy. (J Am Coll Cardiol 1999;34:1435–9) © 1999 by the American
College of Cardiology
The serological association between antibody to the obligate
intracellular bacterium Chlamydia pneumoniae (CPn) and
coronary artery disease (CAD) was first reported in 1988 (1)
and has subsequently been confirmed by numerous serolog-
ical studies (2). Furthermore, CPn antigen and DNA are
commonly found in atherosclerotic plaque (3,4). Intranasal
inoculation of the organism in rabbits has also been shown
to induce aortic inflammatory changes consistent with early
See page 1440
atherosclerosis (5) and to exacerbate disease progression (6).
Such changes could be prevented by antichlamydial treat-
ment with azithromycin (6). However, not all patients with
CAD will have been infected with CPn, and antibiotics are
only indicated for those who have infection. A simple
method for diagnosing current vascular infection with CPn
is required. Previous studies have used the presence of IgG
and IgA antibody to CPn as a proxy for chronic infection,
but the validity of this approach is uncertain (7). C.
pneumoniae infection generally starts in the respiratory tract
and probably disseminates systemically in the blood stream
within alveolar macrophages (8). We therefore assessed the
prevalence of CPn DNA in the blood mononuclear cells of
1,205 patients referred for coronary arteriography and cor-
related the results with clinical and other parameters.
METHODS
This study was approved by the local regional ethics
committee. Subjects were recruited consecutively from in-
dividuals referred for diagnostic and interventional coronary
arteriography to the Wessex Cardiothoracic Unit, a tertiary
referral center, from the end of August 1997 to the
beginning of March 1998. Because they were likely to form
a small group, subjects under 30 were excluded. A few
subjects who did not have blood taken during their current
admission were also excluded. Data available included a full
blood count and, in most cases, indirect fibrinogen levels
and fasting lipids. From each subject, 4 to 5 mls of blood
collected into a tube containing ethylenediaminetetraacetic
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acid (EDTA), were available for serology and for the
detection of CPn DNA by the polymerase chain reaction
(PCR). Cardiac risk factors were recorded, and hypercho-
lesterolemia was diagnosed if the fasting total cholesterol
was greater or had ever been greater than 5.2 mmol/l. A
family history of CAD in a sibling, parent, grandparent or
sibling of a parent was recorded. The Carstairs deprivation
score standardized against national data was calculated from
1991 UK census data (Manchester Information, Datasets
and Associated Services) using the residential postcode and
census enumeration district. Coronary arteriograms were
interpreted by a consultant cardiologist and classified as
“normal,” “minor irregularities” or “significant disease.”
Blood mononuclear cell PCR. EDTA blood was col-
lected from patients around the time of cardiac catheteriza-
tion. Samples were stored overnight at 4°C for processing
the next day. The plasma was clarified by centrifugation and
the supernatant stored at 272°C for serology. Blood cells
were mixed with an equal volume of phosphate buffered
saline (PBS) and layered onto 3 ml of Lymphoprep (Ny-
comed, Denmark). The mononuclear cell layer, which also
contained platelets, was then collected after centrifugation
at 500g for 15 min, washed twice in PBS and stored at
272°C. DNA was prepared from the blood mononuclear
cells by conventional methods involving digestion with
proteinase K, extraction with phenolchloroform, precipita-
tion with sodium acetate-ethanol and the addition of 50 ml
of distilled water. To check for PCR inhibitors, 3 ml of
extracted DNA was spiked with 5 pg of lambda phage
DNA followed by PCR with lambda specific primers (9). C.
pneumoniae PCR (10) was performed using 3 ml DNA at
the original concentration and where inhibition was de-
tected, at a 10-fold dilution. Amplification products were
visualized by electrophoresis on a 2% agarose gel and
staining with ethidium bromide. Stringent precautions were
taken against DNA contamination. Negative controls (dis-
tilled water) were used during DNA extraction and inter-
spersed every five to seven samples during PCR. To control
sensitivity, a positive control was used consisting of CPn
DNA equivalent to 1–10 elementary bodies in 3 ml water.
Serology. A time-resolved fluoroscopic immunoassay was
used (11). Antigen was whole, purified CPn organisms
(VR1310) and the labelling agent was Europium-labelled
streptavidin (Wallac Oy, Finland). Antibody levels were
measured as fluorescence counts using a Wallac 1234
fluorometer.
Data analysis. Conditional multiple logistic regression
(SPSS version 8) was used to explore possible associations of
the presence of CPn DNA and conventional coronary risk
factors with CAD. Of those subjects who did have CAD,
possible associations of the presence of CPn DNA with
indirect fibrinogen and various hematological variables were
investigated after adjusting for age, smoking and month of
recruitment. The two-tailed t test was used to compare
continuous variables with normal distributions and the
chi-square test used for categorical variables. The distribu-
tion of Carstairs score was skewed and subjects were
categorized into three groups of equal size.
RESULTS
Subjects recruited. One thousand two hundred five sub-
jects were recruited (804 men, 401 women). Significant
CAD was found by coronary arteriography in 669 (83.2%)
men and 244 (60.8%) women while 135 men and 157
women had normal coronary arteries or coronary arteries
with mild irregularities only. Of these latter subjects, 73
(54.1%) men and 81 (51.6%) women had been investigated
for chest pain; the majority of the remainder had valvular
heart disease. As expected, the prevalence of conventional
coronary risk factors, apart from deprivation as measured by
the Carstairs score, was greater in those with CAD (Table
1). The Carstairs score takes into account unemployment,
social class, overcrowding and car ownership and 62.5% of
all subjects had a Carstairs score that was better than the
national average while scores were unavailable for 5.1% of
subjects.
C. pneumoniae DNA in blood mononuclear cells. One
hundred subjects (8.3%) had CPn DNA in their blood
mononuclear cells. Men with CAD were significantly more
likely to have circulating CPn DNA than men with normal
coronaries (Table 1), but this difference was not seen in
women. Among men with CAD, those who were positive
for CPn had higher mean platelet counts (Table 2). Mean
monocyte counts and indirect fibrinogen levels were also
higher, but not significantly so. Similar comparisons were
not made among women because the number of subjects
was smaller.
Serology. Plasma samples were assayed in duplicate, with
intra- and interassay coefficients of variation of 4% and 20%,
respectively. Antibody to CPn showed a bimodal distribu-
tion. For analysis, the cut-off point for seropositivity was
predefined as the value midway between the two peaks. Men
were more likely to be seropositive than women, but no
association of serology with CAD was observed for either
sex (Table 1). Subjects who were seropositive were more
likely to have CPn DNA in their blood mononuclear cells,
but this was not statistically significant (76/834 vs. 23/346,
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
CPn 5 Chlamydia pneumoniae
OR 5 odds ratio
PBS 5 phosphate buffered saline
PCR 5 polymerase chain reaction
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odds ratio [OR] 5 1.4, 95% confidence interval [CI] 5 0.9
to 2.3).
DISCUSSION
Detection of current vascular infection by CPn. We have
shown in a large study that CPn DNA can be detected by
PCR in the blood mononuclear cells of patients referred for
coronary arteriography. This is the first time that the clinical
and hematological correlates of vascular chlamydial infec-
tion have been assessed in patients clearly shown to be
infected because of the presence of circulating CPn DNA.
In both laboratory animals (12) and human subjects (3), the
persistence of vascular CPn DNA has been associated with
the presence of viable organism. Other studies have at-
tempted to equate the persistence of specific IgG and IgA
antibody to CPn to the presence of chronic infection with
the organism. However, data on the serological response
associated with culture confirmed chronic CPn infection
are sparse, and no generally agreed standards for chlamydial
serology exist. Culture confirmed chronic respiratory infec-
tion with CPn is not always associated with a specific
antibody response (13), and it is often not possible to predict
subjects with CPn in their blood vessels on the basis of
their serology (14,15). A recent autopsy study of young
Alaskan natives (mean age 34.1) did find that subjects who
had CPn in their blood vessels were more likely to have had
a specific IgG titre of $128 an average 8.7 years before
death (16). However, that serology is a blunt predictive tool
was demonstrated by the fact that 15 of 32 subjects with a
prior titre of $128 were positive for CPn compared with
three of seven subjects without measurable antibody. Cul-
ture of CPn is an exacting and tedious procedure and is not
a feasible option for the routine detection of vascular
infection with this organism. Our results suggest that for














Age (yrs) 62.4 6 10.1† 57.6 6 12.1† 66.6 6 9.4‡ 62.6 6 10.9‡
Hypercholesterolemia 514 (76.8%) 81 (60.0%) 2.2 (1.5–3.3) 208 (85.2%) 105 (66.9%) 2.9 (1.8–4.6)
Hypertension 221 (33.0%) 26 (19.3%) 2.1 (1.3–3.3) 113 (46.3%) 48 (30.6%) 2.0 (1.3–3.0)
Diabetes 79 (11.8%) 9 (6.7%) 1.9 (0.9–3.8) 34 (13.9%) 9 (5.7%) 2.7 (1.2–5.7)
Family history of CAD 359 (53.7%) 49 (36.3%) 2.0 (1.4–3.0) 150 (61.5%) 67 (42.7%) 2.1 (1.4–3.2)
Carstairs score§
Upper third 210 (32.8%) 42 (33.3%) 1.0 (0.7–1.5) 78 (33.5%) 47 (32.6%) 1.1 (0.7–1.7)
Lower third 203 (31.7%) 41 (32.5%) 1.0 (0.7–1.5) 86 (36.9%) 57 (39.6%) 1.0 (0.6–1.5)
Smoking (current/ex) 523 (78.2%) 90 (66.7%) 1.8 (1.2–2.7) 130 (53.3%) 81 (51.2%) 1.1 (0.7–1.6)
Circulating C. pneumoniae DNA1ve 59 (8.8%) 4 (2.9%) 3.2 (1.1–8.9)¶ 20 (8.2%) 17 (10.8%) 0.7 (0.4–1.5)
Seropositive# 492 (74.8%) 97 (73.5%) 1.1 (0.7–1.6) 148 (62.2%) 97 (63.8%) 1.0 (0.6–1.4)
*Unadjusted odds ratio (95% confidence interval); †‡p , 0.001 (2 sample t tests); §Carstairs score available for 766 men and 377 women; ¶3.4 (1.2–9.6) after adjusting for age
(continuous variable), month of recruitment, family history of CAD, smoking (current, ex, never), hypercholesterolemia, hypertension and diabetes (categorical variables) with
conditional multiple logistic regression, 3.3 (1.1–9.5) after adjusting for Carstairs score (thirds) in addition (n 5 766); #Serology results available for 790 men and 390 women.





(n 5 595) p* p†
Full blood count (g/l) 141.6 6 15.8 140.3 6 15.5 0.5 0.6
White cell count (109/l) 8.1 6 3.1 7.8 6 2.2 0.2 0.2
Platelets (109/l) 238.4 6 69 221.9 6 57 0.04 0.03
Neutrophils (109/l) 5.1 6 2.5 4.8 6 1.9 0.2 0.2
Lymphocytes (109/l) 2.1 6 0.8 2.1 6 0.8 0.8 0.9
Monocytes (109/l) 0.7 6 0.4 0.6 6 0.3 0.08 0.06
Eosinophils (109/l) 0.2 6 0.2 0.2 6 0.1 0.8 0.8
Basophils (109/l) 0.07 6 0.06 0.07 6 0.05 0.8 0.8
Indirect fibrinogen (g/l) 4.5 6 1.5 4.1 6 1.2 0.08 0.06
(n 5 51) (n 5 541)
*2 sample t tests (2 tailed); †Multiple linear regression adjusting for age (continuous variable), month of recruitment and smoking
(current, ex or never).
CPn 5 C. pneumoniae.
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CPn vascular infection, as for C. trachomatis genital tract
infection, PCR or other nucleic acid-based amplification
procedures are the most appropriate method for detecting
current infection (17).
One limitation of blood mononuclear cell PCR is that
infection in the blood does not necessarily imply infection of
blood vessels. Also, as infection of blood vessels by CPn in
living subjects cannot generally be diagnosed, the sensitivity
and specificity of blood mononuclear cell PCR for diagnos-
ing such infection is unknown. To distinguish between
acute and chronic infection, future studies will need to test
subjects on more than one occasion to document the
persistence of circulating CPn DNA. Such studies will also
help determine the reproducibility of this test.
Association of CPn infection and CAD. Our study
population was typical in that it showed the expected
correlations with known risk factors of coronary disease. In
males, interestingly, circulating CPn DNA was a stronger
predictor of CAD than any of the known cardiac risk
factors, with an adjusted odds ratio of 3.4 although the
prevalence of vascular CPn infection was low. By contrast,
in women, the presence of CPn DNA was not a predictor of
CAD. The reason for this is unknown, but aortic stenosis
has been associated with CPn infection (18), and approxi-
mately half the subjects with normal coronary arteries had
valvular heart disease. Nevertheless, exclusion of these
subjects did not significantly alter the results of the analysis.
Among men with CAD, those with CPn DNA had higher
platelet counts, a feature of some infectious diseases al-
though not previously reported for CPn. Previous studies
have reported that CPn infection is associated with raised
fibrinogen levels and that this may explain the increased
cardiovascular risk (19). However, in this study, indirect
fibrinogen levels were not significantly raised. Men were
more likely than women to be seropositive for CPn as has
been widely reported, but in neither sex was there an
association of specific antibody with CAD, in agreement
with several recent studies (20,21) including two that were
prospective (22,23).
Population differences in the prevalence of CPn infec-
tion. During the course of this study, a similar but smaller
study was published with dramatically different results (24).
In Umeå, Northern Sweden, a remarkable 59.4% of 101
patients attending for coronary arteriography (mean age 64)
were found to have CPn DNA as were 46% of 52 blood
donors (mean age 49). Also, 11 of 14 (78.6%) patients found
to have normal coronary arteries were positive for CPn
compared with 49 of 86 (57%) patients with CAD. The
much higher prevalence of CPn infection reported from
Umeå might reflect population or methodological differ-
ences. Epidemics of CPn respiratory disease have been
described throughout Scandinavia and an unusual 94% of
patients and 90% of blood donors were seropositive for
CPn, possibly the highest seroprevalence rates ever re-
ported. To exclude the possibility that methodological
differences may account for our differing results, we retested
specimens from our all male subjects with normal coronary
arteries using the touch-down PCR method of the Swedish
study, but found only one more positive result. It is likely,
therefore, that there are genuine population differences, but
further studies are necessary to clarify these points.
Antibiotic intervention trials. An association between
circulating CPn DNA and CAD does not necessarily imply
causation. We recently found that patients undergoing redo
coronary artery bypass graft surgery were just as likely to
have CPn in their new internal mammary artery grafts as in
their failed grafts (9). Also, the Alaskan study above found
no difference in disease severity between coronary artery
segments that had evidence for CPn and those that did not.
However, a small secondary prevention trial has reported
that azithromycin reduces the incidence of further adverse
coronary events following myocardial infarction (25). A
second study also reported significant benefits after thirty
days follow-up but not after six months (26), while prelim-
inary reports from a third study also found no benefit (27).
Further trials are under way, with one trial giving antibiotics
for periods of up to one year without evidence of prior
infection (28). Antimicrobials are only likely to benefit those
who are currently infected and CPn can be considered
neither universal nor the only organism that might be
important in CAD. For reasons of appropriate prescribing
alone, antimicrobials should only be given to subjects in
whom there is good reason to believe there is current CPn
infection. In our population many CAD patients did not
have circulating CPn DNA. Although further research is
required, the demonstration of circulating CPn DNA in
blood may be a useful, possibly prognostic test for selecting
patients for antibiotic trials designed to clarify the role of
CPn in CAD.
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